Top-News

Idorsia Aktie News

Aktie
WKN:  A2DTEB ISIN:  CH0363463438 US-Symbol:  IDRSF Branche:  Biotechnologie Land:  Schweiz
3,845 CHF
+0,00 CHF
0,00%
4,1021 € 09.12.25
Depot/Watchlist
Marktkapitalisierung *
618,49 Mio. €
Streubesitz
55,25%
KGV
-0,58
Dividende
11,03 €
Dividendenrendite
268,74%
Index-Zuordnung
-

Idorsia News

09.12.25 - GlobeNewswire
Idorsia’s treatment for insomnia disorder wins the inaugural Prix Galien Bridges Award in the ‘Best Biotechnology & Pharmaceutical Product’ category
Idorsia’s dual orexin receptor antagonist, the first and only drug of its kind approved in Europe for the treatment of insomnia disorder, has been awarded the inaugural Prix Galien ...
10.11.25 - GlobeNewswire
Idorsia’s aprocitentan improved key prognostic indicators in patients with difficult-to-control hypertension
New analysis from landmark Phase 3 PRECISION trial published in the Journal of Hypertension highlights aprocitentan led to improvements in dipping pattern and BP load ...
05.11.25 - GlobeNewswire
Idorsia to present new aprocitentan insights at ASN Kidney Week & AHA Scientific Sessions
New analysis confirms reductions in blood pressure and albuminuria by aprocitentan in patients with true resistant hypertension and high cardiovascular risk – including chronic ...
30.10.25 - GlobeNewswire
QUVIVIQ sales up >130% driving Idorsia toward profitability – 9M 2025 results
Ad hoc announcement pursuant to Art. 53 LR
10.10.25 - GlobeNewswire
Idorsia successfully completes an upsized offering of shares – funding the company to overall profitability
Ad hoc announcement pursuant to Art. 53 LR
09.10.25 - GlobeNewswire
Idorsia launches an offering of registered shares – to fund the company to overall profitability
Ad hoc announcement pursuant to Art. 53 LR
22.09.25 - GlobeNewswire
Global expansion of Idorsia’s QUVIVIQ continues as Simcere launches in China
Allschwil, Switzerland – September 22, 2025 Idorsia Ltd. (SIX: IDIA) announces that Simcere Pharmaceuticals Group Ltd (2096.HK, “Simcere”) has launched QUVIVIQ ® (daridorexant) ...
19.09.25 - GlobeNewswire
Idorsia’s JERAYGO (aprocitentan) approved in Switzerland for the treatment of resistant hypertension
Idorsia receives approval from Swissmedic for JERAYGO ™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension. ...
10.09.25 - GlobeNewswire
Idorsia shares new analyses of daridorexant for patients with insomnia at World Sleep 2025
Allschwil, Switzerland – September 10, 2025 Idorsia Ltd (SIX: IDIA) shares new analyses of daridorexant for patients with insomnia and further characterizes insomnia disorder at ...
08.09.25 - GlobeNewswire
Idorsia highlights very low real-world abuse potential of DORA class for insomnia treatment at WSC 2025
Analysis of the FAERS database shows that the real-​world abuse potential of the DORA class is very low and markedly less than those seen for other scheduled and non-​scheduled ...
05.09.25 - GlobeNewswire
Idorsia to collaborate with two leading academic medical centers to launch IMPACT-HTN – a US initiative to transform care for patients with difficult-to-control hypertension
Multi-​phase program to standardize treatment, generate real-​world evidence and explore AI-​powered tools to improve outcomes for hypertension patients Allschwil, Switzerland & ...
03.09.25 - GlobeNewswire
Invitation to Idorsia’s aprocitentan (TRYVIO/JERAYGO) investor Q&A webcast and conference call
Idorsia will host a live investor Q&A webcast and conference call following the publication of the  OnDemand investor webcast outlining how TRYVIO™ (aprocitentan) – the first and only ...
01.09.25 - GlobeNewswire
Idorsia furthers the science of sleep and insomnia at World Sleep 2025
Allschwil, Switzerland – September 1, 2025 Idorsia Ltd (SIX: IDIA) continues its commitment to furthering the science of sleep and insomnia with a symposium and eight poster ...
28.08.25 - GlobeNewswire
Idorsia’s TRYVIO – First FDA-approved therapy to target the endothelin pathway for systemic hypertension
Allschwil, Switzerland – August 28, 2025 Idorsia Ltd (SIX: IDIA) releases an OnDemand investor webcast outlining how TRYVIO™ (aprocitentan) – the first and only hypertension therapy ...
27.08.25 - GlobeNewswire
Idorsia successfully completes convertible bonds restructuring
Ad hoc announcement pursuant to Art. 53 LR
19.08.25 - GlobeNewswire
TRYVIO™ (aprocitentan) now included in ACC/AHA Clinical Practice Guidelines for the treatment of hypertension
The updated recommendations now include TRYVIO™ (aprocitentan) – the first and only hypertension treatment targeting the endothelin pathway. Endothelin is upregulated in ...
19.08.25 - GlobeNewswire
Idorsia publishes end results of repurchase offer for its 2025 and 2028 convertible bonds
Ad hoc announcement pursuant to Art. 53 LR
12.08.25 - GlobeNewswire
TRYVIO nominated for the 2025 Prix Galien USA “Best Pharmaceutical Product”
Allschwil, Switzerland – August 12, 2025 Idorsia Ltd (SIX: IDIA) announced today that The Galien Foundation, the premier global institution dedicated to honoring innovators in life ...
11.08.25 - GlobeNewswire
Idorsia publishes interim results of repurchase offer for its 2025 and 2028 convertible bonds
Ad hoc announcement pursuant to Art. 53 LR
30.07.25 - GlobeNewswire
Strong sales acceleration of QUVIVIQ drives Idorsia toward profitability – H1 2025 results
Ad hoc announcement pursuant to Art. 53 LR

Newssuche

Videos

newspaper
08.12.25 +5,61%
Technical Trading: Die besten 3 Tage
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »